ClinicalTrials.gg
CompletedNCT07948382Updated Nov 19, 2026

Lower Urinary Tract Symptoms in Parkinson's Disease and Changes During Kegel Exercises

An interventional study of Kegel Exercises (Pelvic Floor Muscle Training) in PARKINSON DISEASE (Disorder) and Lower Urinary Tract Symptoms, sponsored by Sheikh Zayed Federal Postgraduate Medical Institute. Completed at 1 site in Pakistan. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Sheikh Zayed Federal Postgraduate Medical Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2026, registered Nov 2026).
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 34 studies in Parkinson Disease with a site in Pakistan — 14 open to participants now, 15 under way, none of them phase 3. Parkinson Disease · Pakistan.

Enrollment
3rd of 30
100 · median 42
Started
2026
with 8 others
No phase
30 of 34
14 open now
Registered
34th of 34
by date

Among the 34 studies in Parkinson Disease with a site in Pakistan, this one is the 3rd largest by enrollment of the 30 interventional ones that give a count, is one of 9 that started in 2026, is one of 30 with no phase, and was the 34th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

14 of the 34 studies in Parkinson Disease with a site in Pakistan are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Parkinson Disease with a site in Pakistan, or all of them as a file.
02

Study summary

This study aimed to investigate the frequency and patterns of lower urinary tract symptoms (LUTS) in patients with Parkinson's disease (PD) and evaluate changes in urinary symptoms during a structured 12-week Kegel exercise programme.

This prospective, single-arm, non-randomised interventional study was conducted at Shaikh Zayed Hospital, Lahore, Pakistan, between June and September 2026. A total of 100 patients with Parkinson's disease, aged 40-80 years, underwent baseline assessment. Of these, 66 participants with urinary symptoms entered a 12-week Kegel exercise programme, while 34 participants without urinary symptoms underwent baseline assessment only.

Participants receiving the intervention were instructed to perform 45 pelvic floor muscle contractions daily, divided into three sets of 15 contractions. Follow-up assessments were conducted at Weeks 6 and 12.

Urinary symptoms and associated quality-of-life outcomes were evaluated using the International Prostate Symptom Score (IPSS), International Consultation on Incontinence Questionnaire-Overactive Bladder (ICIQ-OAB), urinary quality-of-life questionnaires, and three-day bladder diaries. Exercise adherence and patient-reported improvement were also assessed.

The study aimed to characterise urinary symptom patterns in Parkinson's disease and describe changes observed during the Kegel exercise programme. Because the study did not include a control group, it was not designed to establish a causal treatment effect.

Read the detailed description

Lower urinary tract symptoms (LUTS) are common non-motor manifestations of Parkinson's disease (PD) and can negatively affect sleep, daily functioning, and quality of life. These symptoms include increased urinary frequency, urgency, nocturia, urinary incontinence, hesitancy, weak urinary stream, and incomplete bladder emptying. Pelvic floor muscle training, commonly known as Kegel exercises, represents a non-pharmacological approach to managing urinary symptoms. However, evidence regarding changes in specific urinary symptom domains during structured pelvic floor training in patients with Parkinson's disease remains limited.

The study was designed to characterise the distribution of storage-only, voiding-only, and mixed urinary symptoms among patients with Parkinson's disease and to investigate changes in urinary symptoms during a 12-week structured Kegel exercise programme.

This prospective, single-centre, single-arm, non-randomised interventional study was conducted in the Department of Neurology at Shaikh Zayed Hospital, Lahore, Pakistan. Recruitment was undertaken from 14 to 28 June 2026, and the study period extended to 20 September 2026.

A total of 100 consecutive patients aged 40-80 years, diagnosed with Parkinson's disease according to Movement Disorder Society criteria, were enrolled. All participants underwent baseline clinical assessment, including demographic characteristics, Parkinson's disease duration, motor severity, cognitive function, and urinary symptoms.

Participants with known prostatic disease or malignancy, urethral stricture, other neurogenic bladder disorders, active urinary tract infection, indwelling urinary catheters, recent urological surgery, or medication affecting bladder function were excluded.

At baseline, participants were categorised according to the presence or absence of LUTS. Of the 100 participants, 66 with LUTS entered the 12-week Kegel exercise intervention, while 34 without LUTS underwent baseline assessment only.

The Kegel exercise programme consisted of 45 pelvic floor muscle contractions daily, performed in three sets of 15 repetitions. Participants received instruction on correct pelvic floor muscle contraction techniques. A nurse practitioner or principal investigator assessed contraction technique, and additional instruction was provided when necessary. Exercise technique was reviewed at Week 6.

Participants receiving the intervention underwent urinary assessments at baseline, Week 6, and Week 12. The International Prostate Symptom Score (IPSS) was used to assess overall urinary symptom severity. Storage and voiding symptom domains were examined separately. The International Consultation on Incontinence Questionnaire-Overactive Bladder (ICIQ-OAB) was used to evaluate overactive bladder symptoms and associated bother, while quality-of-life questionnaires assessed the impact of urinary symptoms on daily life.

Three-day bladder diaries were used to record urinary frequency, nocturia, urinary leakage, urgency episodes, and mean voided volume. Self-reported adherence to Kegel exercises and Patient Global Impression of Improvement (PGI-I) were assessed during follow-up.

Statistical analyses included baseline comparisons between participants with and without LUTS and repeated-measures analyses of urinary outcomes among intervention participants. Associations between exercise adherence and changes in urinary symptoms were also explored. Outcome-specific complete-case analyses were performed without imputing missing data.

The study was conducted with approval from the institutional Technical and Ethical Review Committee (TERC), approval number TERC/SCI/INT/2026/414, dated 10 June 2026. Written informed consent was obtained before participant enrolment.

The study was intended to describe urinary symptom patterns and within-participant changes during structured Kegel training. Its uncontrolled design limits causal interpretation and does not permit definitive conclusions regarding treatment efficacy.

03

Conditions studied

  • PARKINSON DISEASE (Disorder)
  • Lower Urinary Tract Symptoms

Keywords

  • Kegel Exercises
  • Pelvic Floor Muscle Training
  • Urinary Incontinence
  • Overactive Bladder
  • Nocturia
  • Urinary Urgency
  • Urinary Frequency
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients aged 40-80 years.

Diagnosis of Parkinson's disease according to Movement Disorder Society diagnostic criteria.

Patients with or without lower urinary tract symptoms (LUTS).

Ability and willingness to provide written .

Exclusion criteria

Exclusion Criteria:

Known prostatic disease or .

Urethral stricture.

Other neurogenic bladder disorders.

Active urinary tract infection.

Indwelling urinary catheterisation.

History of urological surgery within the preceding six months.

Use of medications affecting bladder function.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Kegel Exercise Group

    This arm included 66 patients with Parkinson's disease and lower urinary tract symptoms (LUTS) who participated in a structured 12-week Kegel exercise programme. Participants performed 45 pelvic floor muscle contractions daily, divided into three sets of 15 contractions. Correct contraction technique was assessed at baseline and reviewed at Week 6. Urinary symptoms, bladder diary measures, quality of life, and exercise adherence were assessed during follow-up at Weeks 6 and 12.

    Behavioral: Kegel Exercises (Pelvic Floor Muscle Training)

Interventions

  • BehavioralKegel Exercises (Pelvic Floor Muscle Training)

    Participants received a structured pelvic floor muscle training programme consisting of 45 Kegel contractions per day, performed in three sets of 15 contractions for 12 weeks. Correct pelvic floor contraction technique was assessed by the investigator or nurse practitioner, with additional instruction provided when needed. Technique was reviewed at Week 6. Participants were assessed at baseline, Week 6, and Week 12.

    Also known as: Pelvic Floor Muscle Exercises

06

What researchers measure

Primary outcomes

  1. Prevalence of Lower Urinary Tract Symptoms

    Percentage of participants with Parkinson's disease presenting with lower urinary tract symptoms at baseline, including storage, voiding, or mixed urinary symptoms. Prevalence was calculated as the number of participants with LUTS divided by the total number assessed, multiplied by 100.

    Time frame: Baseline

Secondary outcomes

  1. Change in Total IPSS

    Change in International Prostate Symptom Score (0-35). Higher scores indicate more severe urinary symptoms.

    Time frame: Baseline, Week 6, Week 12

07

Study locations

1 site
  • Federal Post Graduate Medical Instituite, Shaikh Zayed Hospital, Lahore
    Lahore, Punjab Province, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Individual participant-level data will not be made available for sharing. Aggregated study findings and summary data may be provided by the corresponding author upon reasonable request, subject to institutional policies and protection of participant confidentiality.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2026 to primary completion in Sep 2026, 3 months.

Of 1,295 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 3 months is below that.

Counting every sponsor, half of 1,371 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartActual
Jun 14, 2026
Primary completionActual
Sep 20, 2026
CompletionActual
Sep 20, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948382
Lead sponsor
Sheikh Zayed Federal Postgraduate Medical Institute
Responsible party
Tahira Shaukat (Professor, Sheikh Zayed Federal Postgraduate Medical Institute) — Principal investigator
First posted
Nov 19, 2026
Start date
Jun 14, 2026
Primary completion
Sep 20, 2026
Completion
Sep 20, 2026
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion